Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.
A simple online search for semaglutide, the active ingredient in Ozempic or Wegovy, can lead consumers down a rabbit hole of ...
The UK’s drug’s watchdog has warned people over the use of counterfeit medications which could contain insulin - with many ...
A recent poll found that about 15.5 million Americans have used injectable diabetes medicines like Ozempic and Wegovy to lose ...
Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...
ScienceAlert on MSN3d
Experts Are Concerned Drugs Like Ozempic May Cause Muscle LossMedications like Ozempic and Wegovy are famous for their weight loss benefits, but some scientists want to know more ...
Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, ...
In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...
A more tragic irony in the town is an obesity crisis among residents living in the shadow of the massive Wegovy-making plant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback